Category - Executive Moves

pSivida (NASDAQ:PSDV) has appointed Nancy Lurker as president, CEO and a member of the board, succeeding Paul Ashton, who has resigned to pursue other interests.Ms. Lurker, a seasoned healthcare executive, brings strong...

Closely-held Interface Biologics (IBI) has appointed Wendy Naimark as VP of research & development.Wendy joins IBI after five years as senior director, clinical and preclinical sciences at 480 Medical, an early...

Knight Therapeutics (TSX:GUD) has closed on a $1-million equity investment in closely-held 3D Signatures, which has completed a business combination and public listing transaction.3D is a personalized medicine company...

Shawn Aspden, a 20-year veteran of the Canadian capital markets, has joined Bloom Burton & Co. as managing director. Mr. Aspden recently served was vice chairman and head of North American institutional equity sales...

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) said Karen Licitra will be joining the company’s board of directors. Ms. Licitra has a track record of accomplishments in sales, marketing, commercial and general...

Vital Therapies (NASDAQ:VTL) appointed Faheem Hasnain to the board, effective immediately.Mr. Hasnain served as president, CEO and as a director of Receptos from November 2010 to August 2015, when it was purchased by...

Corey Davis has joined H.C. Wainwright in equity research as a managing director, covering specialty pharmaceuticals.Dr. Davis has 19 years of sell-side experience, covering specialty pharmaceutical companies, spending...

Oramed Pharmaceuticals (NASDAQ:ORMP) appointed Dr. Roy Eldor to the newly created post of chief medical director. “We are very pleased to welcome Dr. Eldor on board at this pivotal time for Oramed as we head towards a...

ProMIS Neurosciences (TSX:PMN) has appointed Johanne Kaplan to the post of chief development officer to focus on supporting the design and execution of the company’s development programs and partnering efforts.

Closely-held Soricimed Biopharma has announced the members of its newly formed Clinical Advisory Board (CAB). The CAB, comprising key thought leaders in the treatment of cancer and novel anti-cancer targets, will...